Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) EBT Margin (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed EBT Margin for 16 consecutive years, with 95.16% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 18673.0% to 95.16% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 59.29% through Dec 2025, up 5779.0% year-over-year, with the annual reading at 59.29% for FY2025, 5779.0% up from the prior year.
  • EBT Margin hit 95.16% in Q4 2025 for Ligand Pharmaceuticals, down from 122.24% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 366.22% in Q1 2024 to a low of 157.45% in Q2 2024.
  • Historically, EBT Margin has averaged 28.52% across 5 years, with a median of 22.21% in 2022.
  • Biggest five-year swings in EBT Margin: soared 23994bps in 2024 and later plummeted -47691bps in 2025.
  • Year by year, EBT Margin stood at 31.7% in 2021, then skyrocketed by 51bps to 47.91% in 2022, then grew by 27bps to 60.84% in 2023, then tumbled by -250bps to 91.56% in 2024, then surged by 204bps to 95.16% in 2025.
  • Business Quant data shows EBT Margin for LGNDZ at 95.16% in Q4 2025, 122.24% in Q3 2025, and 23.56% in Q2 2025.